Revlimid Sert Capsule 15 Mg

Description

Composition

Each capsule encapsulates 15 mg of lenalidomide, accompanied by auxiliary substances such as lactose anhydride, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, gelatin, shellac, propylene glycol, potassium hydroxide, titanium dioxide (E171), and black iron oxide (E172).

Indications

Revlimid finds its medical prowess in the treatment of multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma in adults. Additionally, it addresses anemia associated with rare bone marrow disorders, including myelodysplastic syndromes.

Mode of Action

The therapeutic journey of Revlimid involves a multifaceted impact on the body’s immune system and a direct assault on cancer cells. Its mechanisms include the cessation of cancer cell development, inhibition of blood vessel growth in cancerous regions, and stimulation of the immune system to combat cancer cells.

Side Effects

While offering therapeutic benefits, Revlimid Sert Capsule 15 Mg may present side effects. Reporting any such effects is crucial for swift identification of new safety information.

Precautions

Caution is advised as Revlimid treatment may reactivate viruses in patients harboring them. Patient disclosure to the healthcare provider about medication use is imperative.

Onset and Effectiveness

Revlimid initiates action within hours of consumption, although noticeable symptom alleviation may not occur immediately. Individual responses vary, with studies indicating a substantial 39-month disease progression-free survival for patients under Revlimid, emphasizing its effectiveness.

Common Side Effects

Revlimid may induce common and mild side effects, including diarrhea, fatigue, decreased blood cell levels, constipation, skin rash or itchiness, cough, insomnia, edema, weakness, dizziness, nausea or vomiting, fever, respiratory infections, gastroenteritis, pain in back or joints, headache, muscle cramps, and nosebleeds.

Pregnancy and Revlimid Sert Capsule 15 Mg

Revlimid is contraindicated during pregnancy due to potential harm to the fetus. Women are advised to avoid pregnancy for at least four weeks before, during, and after Revlimid therapy. The medication, a thalidomide analogue, holds teratogenic potential, necessitating immediate discontinuation if pregnancy occurs during therapy.

Discontinuation and Metabolism

Upon discontinuation, Revlimid Sert Capsule 15 Mg remains in the system for up to four weeks, with metabolism primarily via renal excretion. Kidney function significantly influences clearance.

Drug Interactions

Revlimid Sert Capsule 15 Mg interacts with 263 drugs and exhibits three disease interactions. Vigilance is required, considering the 94 major, 168 moderate, and 1 minor interactions. Examples include acyclovir, allopurinol, amlodipine, dexamethasone, folic acid, and many others.

Mitigating Drug Interactions

Mitigating the risk of drug interactions involves comprehensive steps: informing healthcare providers of all medications, regular monitoring, limiting certain foods and drinks, adherence to instructions, and utilizing drug interaction checker tools.

Conclusion

Revlimid Sert Capsule 15 Mg emerges as a pharmaceutical beacon, offering a nuanced approach to various medical conditions. While its therapeutic benefits are evident, caution and adherence to medical guidance remain paramount. This comprehensive exploration aims to empower individuals with knowledge, fostering informed healthcare decisions.

---

Feature	Revlimid Sert Capsule 15 Mg
Composition	15 mg Lenalidomide
Indications	Multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, anemia associated with bone marrow disorders
Mode of Action	Modulation of immune system functions, direct attack on cancer cells
Side Effects	Common side effects include diarrhea, fatigue, decreased blood cell levels, constipation, skin rash, cough, insomnia, edema, weakness, dizziness, nausea or vomiting, fever, respiratory infections, gastroenteritis, pain in back or joints, headache, muscle cramps, nosebleeds
Availability and Pricing	21 capsules per pack, Retail sale price: 39268.38 TL as of December 25, 2023
Precautions	Caution in virus-carrying patients, immediate reporting of side effects
Onset and Effectiveness	Initiates action within hours, individual response variation, studies indicate 39-month disease progression-free survival
Pregnancy and Revlimid	Contraindicated during pregnancy, avoidance for four weeks before, during, and after therapy due to teratogenic potential
Discontinuation and Metabolism	Stays in the system for up to four weeks post-discontinuation, primarily renal excretion
Drug Interactions	263 known interactions (94 major, 168 moderate, 1 minor) with examples including acyclovir, allopurinol, amlodipine, dexamethasone, folic acid, etc.
Mitigating Drug Interactions	Inform healthcare provider, regular monitoring, limit certain foods, adhere to instructions, use drug interaction checker tools